However, a wide range of anti-TNFα molecules (e.g., infliximab, adalimumab, etanercept, lenercept) have been developed and used for the treatment of both inflammatory conditions, such as rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease, as well as neurodegenerative disorders, e.g., multiple sclerosis (MS) and Alzheimer’s disease (AD) [80]. Here, TNF is linked to early-onset autosomal dominant Alzheimer disease.